Recent advances in cancer stem cell research for cholangiocarcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 19, Issue 6, 2012, Pages 606-613

  Kokuryo, Toshio ^a   Yokoyama, Yukihiro ^a   Nagino, Masato ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer stem cell; Cholangiocarcinoma; Hepatic progenitor cell; Hepatic stem cell

Indexed keywords

ALPHA6 INTEGRIN; ANTINEOPLASTIC AGENT; B RAF KINASE; BETA CATENIN; CD133 ANTIGEN; CD24 ANTIGEN; CYCLOPAMINE; EPITHELIAL CELL ADHESION MOLECULE; FRIZZLED PROTEIN; HERMES ANTIGEN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; RETINOIC ACID; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; STEM CELL ANTIGEN 1; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TUMOR MARKER; WNT PROTEIN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CELL ACTIVATION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; DRUG TARGETING; ENZYME INHIBITION; EPIGENETICS; ERADICATION THERAPY; GENE SILENCING; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER REGENERATION; MALIGNANT TRANSFORMATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PROTEIN BINDING; PROTEIN SYNTHESIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELL RESEARCH; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; FLOW CYTOMETRY; HUMANS; NEOPLASTIC STEM CELLS; STEM CELL RESEARCH; TISSUE THERAPY;

EID: 84872185005     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-012-0542-6     Document Type: Article

References (66)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-7. (Pubitemid 27298715)
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983-8. (Pubitemid 36418143)
3. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030-7.
4. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120(7):1444-50.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-11.
6. Nimura Y. Radical surgery: vascular and pancreatic resection for cholangiocarcinoma. HPB (Oxford). 2008;10(3):183-5. (Pubitemid 352016245)
7. Morise Z, Sugioka A, Hoshimoto S, Kato T, Tanahashi Y, Ikeda M, et al. Patient with advanced intrahepatic cholangiocarcinoma with long-term survival successfully treated with a combination of surgery and chemotherapy. J Hepatobiliary Pancreat Surg. 2008;15(5):545-8.
8. Igami T, Nishio H, Ebata T, Yokoyama Y, Sugawara G, Nimura Y, et al. Surgical treatment of hilar cholangiocarcinoma in the ''new era'': the Nagoya University experience. J Hepatobiliary Pancreat Sci. 2010;17(4):449-54.
9. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005;41(1):5-15. (Pubitemid 40066375)
10. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol. 1989;134(6):1347-63.
11. Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology. 2007;133(3): 937-50.
12. Haratake J, Hashimoto H. An immunohistochemical analysis of 13 cases with combined hepatocellular and cholangiocellular carcinoma. Liver. 1995;15(1):9-15.
13. Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ, et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res. 2010;70(8):3034-41.
14. Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011; 1(1):5.
15. Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47(5):1544-56.
16. Zhang F, Chen XP, Zhang W, Dong HH, Xiang S, Zhang WG, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and doublefluorescence immunostaining evidence. Histopathology. 2008; 52(2):224-32.
17. Alison MR, Vig P, Russo F, Bigger BW, Amofah E, Themis M, et al. Hepatic stem cells: from inside and outside the liver? Cell Prolif. 2004;37(1):1-21. (Pubitemid 38250582)
18. Tischoff I, Wittekind C, Tannapfel A. Role of epigenetic alterations in cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2006;13(4):274-9. (Pubitemid 44111334)
19. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol. 2008;214(1):3-9.
20. Fan L, He F, Liu H, Zhu J, Liu Y, Yin Z, et al. CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer. 2011;11:320.
21. Wang M, Xiao J, Jiang J, Qin R. CD133 and ALDH may be the molecular markers of cholangiocarcinoma stem cells. Int J Cancer. 2011;128(8):1996-7.
22. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol. 2010;45(8):896-902.
23. Yoshikawa S, Zen Y, Fujii T, Sato Y, Ohta T, Aoyagi Y, et al. Characterization of CD133? parenchymal cells in the liver: histology and culture. World J Gastroenterol. 2009;15(39): 4896-906.
24. Leelawat K, Thongtawee T, Narong S, Subwongcharoen S, Treepongkaruna SA. Strong expression of CD133 is associated with increased cholangiocarcinoma progression. World J Gastroenterol. 2011;17(9):1192-8.
25. Riener MO, Vogetseder A, Pestalozzi BC, Clavien PA, Probst- Hensch N, Kristiansen G, et al. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract. Hum Pathol. 2010;41(11):1558-65.
26. Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, et al. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg. 2007;11(4):445-51.
27. Su MC, Hsu C, Kao HL, Jeng YM. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett. 2006;235(1):34-9.
28. Keeratichamroen S, Leelawat K, Thongtawee T, Narong S, Aegem U, Tujinda S, et al. Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival. Int J Oncol. 2011;39(4):873-81.
29. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009;69(14):5627-9.
30. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133? and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118(6):2111-20.
31. Kim H, Park C, Han KH, Choi J, Kim YB, Kim JK, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol. 2004;40(2):298-304.
32. Benko G, Spajic B, Kruslin B, Tomas D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol Oncol. 2011. doi 10.1016/ j.urolonc.2011.03.007
33. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol. 1999;188(2):201-6. (Pubitemid 29253941)
34. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumorinitiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012-24.
35. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, et al. Cancer stem/ progenitor cells are highly enriched in CD133? CD44? population in hepatocellular carcinoma. Int J Cancer. 2010;126(9): 2067-78.
36. Fortunel NO, Otu HH, Ng HH, Chen J, Mu X, Chevassut T, et al. Comment on '''Stemness': transcriptional profiling of embryonic and adult stem cells'' and ''a stem cell molecular signature''. Science. 2003;302(5644):393 (author reply).
37. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, et al. Purification and unique properties of mammary epithelial stem cells. Nature. 2006;439(7079):993-7. (Pubitemid 43292419)
38. Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, Wu H. Lin-Sca-1?CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 2009; 69(22):8555-62.
39. Suzuki A, Zheng Y, Kondo R, Kusakabe M, Takada Y, Fukao K, et al. Flow-cytometric separation and enrichment of hepatic progenitor cells in the developing mouse liver. Hepatology. 2000;32(6):1230-9.
40. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA. 2005;102(19):6942-7. (Pubitemid 40675421)
41. Jin C, Samuelson L, Cui CB, Sun Y, Gerber DA. MAPK/ERK and Wnt/beta-Catenin pathways are synergistically involved in proliferation of Sca-1 positive hepatic progenitor cells. Biochem Biophys Res Commun. 2011;409(4):803-7.
42. Fujio K, Evarts RP, Hu Z, Marsden ER, Thorgeirsson SS. Expression of stem cell factor and its receptor, c-kit, during liver regeneration from putative stem cells in adult rat. Lab Invest. 1994;70(4):511-6. (Pubitemid 24185021)
43. Omori M, Evarts RP, Omori N, Hu Z, Marsden ER, Thorgeirsson SS. Expression of alpha-fetoprotein and stem cell factor/c-kit system in bile duct ligated young rats. Hepatology. 1997;25(5):1115-22.
44. Mansuroglu T, Ramadori P, Dudas J, Malik I, Hammerich K, Fuzesi L, et al. Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma. Lab Invest. 2009;89(5):562-74.
45. Lee D, Do IG, Choi K, Sung CO, Jang KT, Choi D, et al. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol. 2011;25:131-9.
46. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008;22(4):436-48.
47. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133? HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27(12):1749-58.
48. Wu CH, Nusse R. Ligand receptor interactions in the Wnt signaling pathway in Drosophila. J Biol Chem. 2002;277(44): 41762-9. (Pubitemid 35257485)
49. Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, et al. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol. 2005;27(4):973-80.
50. Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell. 1997;90(2):281-91.
51. Ochsner SA, Strick-Marchand H, Qiu Q, Venable S, Dean A, Wilde M, et al. Transcriptional profiling of bipotential embryonic liver cells to identify liver progenitor cell surface markers. Stem Cells. 2007;25(10):2476-87.
52. Yoon HA, Noh MH, Kim BG, Han JS, Jang JS, Choi SR, et al. Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J Gastroenterol. 2011;17(35):4023-30.
53. Tanimizu N, Miyajima A. Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. J Cell Sci. 2004;117(Pt 15):3165-74.
54. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology. 2005;128(5):1354-68.
55. Jinawath A, Akiyama Y, Sripa B, Yuasa Y. Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol. 2007;133(4):271-8.
56. Hirose Y, Itoh T, Miyajima A. Hedgehog signal activation coordinates proliferation and differentiation of fetal liver progenitor cells. Exp Cell Res. 2009;315(15):2648-57.
57. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003;52(5):706-12.
58. Boberg KM, Schrumpf E, Bergquist A, Broome U, Pares A, Remotti H, et al. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol. 2000;32(3):374-80.
59. Huang EH, Heidt DG, Li CW, Simeone DM. Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. Surgery. 2007;141(4):415-9. (Pubitemid 46441320)
60. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008;99(1):100-9. (Pubitemid 351920235)
61. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol. 2010;52(2): 280-1.
62. Pongcharoen P, Jinawath A, Tohtong R. Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells. Clin Exp Metastasis. 2011;28(8):827-39.
63. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol. 2004;51(1):1-28. (Pubitemid 38781748)
64. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-72.
65. Ruiz-Vela A, Aguilar-Gallardo C, Simon C. Building a framework for embryonic microenvironments and cancer stem cells. Stem Cell Rev. 2009;5(4):319-27.
66. Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol. 2010;53(3):568-77.